title: Biological Therapy-Induced Systemic Vasculitis.
abstract: The use of biologics has been associated with the paradoxical development of biologics-induced autoimmune diseases. The purpose of this review was to describe the key immunopathogenic mechanisms involved in the development of these conditions, and to discuss the clinical and laboratory characteristics usually described in the medical literature, reviewing case reports as well as records on national biologic therapies (BIOGEAS, RABBIT, BSRBR-RA, BIOBADAVEN). More than 200 cases have so far been reported, all of them diagnosed on the basis of the histopathology or meeting the ACR/Chapel Hill criteria. Over 75 % of the cases were females with a mean age of 48 ± 5 years. More than 50 % had rheumatoid arthritis. Most of the biologics-associated vasculitis developed in 90 ± 31 days. Complete resolution in almost 75 % of the cases was observed upon treatment discontinuation; however, steroid therapy was indicated for all patients and one death was recorded. The use of cyclophosphamide, rituximab or plasma exchange was reserved for the most severe cases.
authors.affiliation: Centro Nacional de Enfermedades Reumáticas (CNER), Hospital Universitario de Caracas, HUC-UCV, Hospital Universitario de Caracas, Los Chaguaramos, Ciudad Universitaria, UCV, Caracas, 1020, Venezuela. cner.rheumatology@gmail.com.
authors.forename: Luis Arturo
authors.initials: LA
authors.lastname: Gutiérrez-González
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001688:Biological Products / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D056647:Systemic Vasculitis / Q000139:chemically induced*
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products
keywords: ANCA; Biologic therapies; CTLA-4 polymorphisms; Rheumatoid arthritis; Vasculitis